Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

120.69 -6.65 (-5.22%)
Delayed Quote Updated: 11:14 AM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28,963
Open 127.27
Bid (Size) 120.16 (100)
Ask (Size) 121.09 (100)
Prev. Close 127.34
Today's Range 120.69 - 127.27
52wk Range 68.96 - 161.38
Shares Outstanding 98,935,025
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire

Performance

52-Week Range 25.2% below 52-week high
120.69
68.9652W Low 161.3852W High
1 Week 13.7% below 1-week high
120.271W Low 139.861W High

Palvella Therapeutics, Inc. - Common Stock (PVLA) traded between $68.96 and $161.38 over the past 52 weeks and last traded at $120.69, 25.2% below its 52-week high. Over the past week it ranged between $120.27 and $139.86.

Past 12 Months
-13.0%
-20.2%
-18.3%
-2.8%
+20.4%
+58.2%
1W -$18.08
1M -$30.53
3M -$27.08
6M -$3.49
YTD +$20.41
1Y +$44.38

PVLA was +58.2% over the past year, -2.8% over six months, +20.4% year to date, -13.0% in the last week.

12 Months vs Market
PVLA
+58.2%
DIA
+13.0%
SPY
+15.7%
QQQ
+19.3%
IWM
+9.4%

Over the past 12 months PVLA returned +58.2% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.7%, QQQ (Nasdaq 100) +19.3% and IWM (Russell 2000) +9.4%.

Volume & Liquidity 0.14× 3-mo avg
Today 28,963 3-mo avg 213.8K
1W
245.5K
1M
242.0K
3M
213.8K
6M
236.9K
YTD
261.1K
1Y
258.5K

PVLA most recently traded 28,963 shares against a 3-month average daily volume of 213.8K.

More News

Read More
News headline image
Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands ↗
Via MarketBeat
News headline image
Palvella (PVLA) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call ↗
Via Benzinga
News headline image
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
From Palvella Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Palvella Therapeutics, Inc. - Common Stock publicly traded?
Yes, Palvella Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Palvella Therapeutics, Inc. - Common Stock trade on?
Palvella Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Palvella Therapeutics, Inc. - Common Stock?
The ticker symbol for Palvella Therapeutics, Inc. - Common Stock is PVLA on the Nasdaq Stock Market
What is the current price of Palvella Therapeutics, Inc. - Common Stock?
The current price of Palvella Therapeutics, Inc. - Common Stock is 120.69
When was Palvella Therapeutics, Inc. - Common Stock last traded?
The last trade of Palvella Therapeutics, Inc. - Common Stock was at 10/16/26 11:14 AM ET
What is the market capitalization of Palvella Therapeutics, Inc. - Common Stock?
The market capitalization of Palvella Therapeutics, Inc. - Common Stock is 11.94B
How many shares of Palvella Therapeutics, Inc. - Common Stock are outstanding?
Palvella Therapeutics, Inc. - Common Stock has 12B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.